Rheumatoid arthritis

Half of RA patients on biologics will switch: ARAD

Patterns of use for biologics in rheumatoid arthritis are complex, according to Australian research presented at the 2019 ACR/ARP Annual Meeting in Atlanta. According to an analysis of 3,470 participants in ARAD (Australian Rheumatology Association Database) from 2001 to 2018, first-line bDMARDS were largely etanercept (ETA, n=1,414) and adalimumab (ADA, n=1,024), followed by infliximab (INX, n=155), ...

Already a member?

Login to keep reading.

© 2021 the limbic